第一三共/阿斯利康(AZN.US)德曲妥珠單抗新適應症擬優先審評

智通財經

06-10

智通財經APP獲悉，6月10日，CDE官網顯示，第一三共與阿斯利康(AZN.US)共同開發的德曲妥珠單抗被納入擬優先審評行列，單藥適用於治療既往接受過一種治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者。

今年3月，III期研究DESTINY-Gastric04傳來捷報。該研究評估了德曲妥珠單抗(6.4mg/kg)對比雷莫西尤單抗聯合紫杉醇二線治療HER2+不可切除和/或轉移性胃或胃食管交界處腺癌患者的療效和安全性。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542317531"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542317531\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542317531?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-10 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542317531","market":"us","top_or_hot":-1,"title":"第一三共/阿斯利康(AZN.US)德曲妥珠單抗新適應症擬優先審評","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，6月10日，CDE官網顯示，第一三共與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>(AZN.US)共同開發的德曲妥珠單抗被納入擬優先審評行列，單藥適用於治療既往接受過一種治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者。</p><p><img src=\"https://img.zhitongcaijing.com/image/20250610/1749561245361969.png\" title=\"1749561245361969.png\"/></p><p>今年3月，III期研究DESTINY-Gastric04傳來捷報。該研究評估了德曲妥珠單抗(6.4mg/kg)對比雷莫西尤單抗聯合紫杉醇二線治療HER2+不可切除和/或轉移性胃或胃食管交界處腺癌患者的療效和安全性。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>第一三共/阿斯利康(AZN.US)德曲妥珠單抗新適應症擬優先審評</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n第一三共/阿斯利康(AZN.US)德曲妥珠單抗新適應症擬優先審評\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-06-10 21:13</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，6月10日，CDE官網顯示，第一三共與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>(AZN.US)共同開發的德曲妥珠單抗被納入擬優先審評行列，單藥適用於治療既往接受過一種治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者。</p><p><img src=\"https://img.zhitongcaijing.com/image/20250610/1749561245361969.png\" title=\"1749561245361969.png\"/></p><p>今年3月，III期研究DESTINY-Gastric04傳來捷報。該研究評估了德曲妥珠單抗(6.4mg/kg)對比雷莫西尤單抗聯合紫杉醇二線治療HER2+不可切除和/或轉移性胃或胃食管交界處腺癌患者的療效和安全性。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1303646.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2456880835.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1303646.html","article_id":"2542317531","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542317531","pubTimestamp":1749561201,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，6月10日，CDE官網顯示，第一三共與阿斯利康(AZN.US)共同開發的德曲妥珠單抗被納入擬優先審評行列，單藥適用於治療既往接受過一種治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者。今年3月，III期研究DESTINY-Gastric04傳來捷報。該研究評估了德曲妥珠單抗(6.4mg/kg)對比雷莫西尤單抗聯合紫杉醇二線治療HER2+不可切除和/或轉移性胃或胃食管交界處腺癌患者的療效和安全性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4588":"碎股","AZN":"阿斯利康","BK4585":"ETF&股票定投概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC"},"translate_title":"Daiichi Sankyo/AstraZeneca (AZN.US) new indications for trastuzumab to be prioritized for review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"智通財經APP獲悉，6月10日，CDE官網顯示，第一三共與阿斯利康(AZN.US)共同開發的德曲妥珠單抗被納入擬優先審評行列，單藥適用於治療既往接受過一種治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者。今年3月，III期研究DESTINY-Gastric04傳來捷報。該研究評估了德曲妥珠單抗(6.4mg/kg)對比雷莫西尤單抗聯合紫杉醇二線治療HER2+不可切除和/或轉移性胃或胃食管交界處腺癌患者的療效和安全性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}